Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 14, 2004. The report details a share repurchase transaction executed on December 13, 2004, and updates regarding directors' interests in company shares.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks and treasury holdings.
- Shares Repurchased: 750,000 Ordinary Shares
- Repurchase Price: 1,176.21 pence per Share
- Total Treasury Shares Held: 64,198,000
- Shares in Issue (excluding treasury): 5,872,968,459
Material Changes
The primary material change is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 17, 2004. Additionally, the GlaxoSmithKline Employee Trust transferred 118,696 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of operational risks. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 750,000 share repurchase against the stated price of 1,176.21 pence.
- Confirm the updated total share count of 5,872,968,459 shares in issue.
- Note that 64,198,000 shares are currently held in treasury and are excluded from the issued share count.
- Review the impact of the 118,696 shares transferred from the GSK Trust to employee option plan participants.